Back to HOME

Lipoprotein


DATA No : TLP4501 INFORMANT : Kazuo Kondo

NAME : apolipoprotein C-III

COMMON NAME:
SYMBOL: apo C-III
FORMULA: MOL.WT (average) :
BIOLOGICAL ACTIVITY
Function
(1) Apo C -III inhibits activation of LPL by apo C II.(2) Apo C -III inhibits incorporation of apo E-containing lipoproteins (chylomicron remnant) into hepatocytes.22. (3)Apo C -III enhances sphingomyelinase activity, thus being involved in lipid degeneration.(Ref. 4504/4505)
PHYSICAL AND CHEMICAL PROPERTIES
MELTING POINT:Molecular weight:8,751
Isoelectric point:4.7~5.0(Ref. 4501/4502)

BOILING POINT:The number of amino acid residues :79

REFRACTIVE INDEX:Amino acid sequences::Further investigations are required.

OPTICAL ROTATION:Structure:The primary structure of apo C -III is comprised of single-stranded polypeptides. Threonine74 binds to one molecule each of galactose, mannose and galactosamine, in addition to 0 or several molecules of sialic acid. The secondary structure consists of a-helices (17.7%), b-structures (17.7%), b-turns (30.4%), and random structures (34.2%). The secondary structure of apo C III forms amphiphilic helices, and polar amino acids distributed on the opposite side of the structure are involved in lipid binding.

DENSITY:Amino acid compositions (Ref. 4408)

SOLUBILITY:(Ref. 4503)
SPECTRAL DATA
UV SPECTRA:

IR SPECTRA:

NMR SPECTRA:

MASS SPECTRA:

OTHER SPECTRA:
CHROMATOGRAM DATA
Method of purification
After centrifugation, VLDL was separated from plasma by ultracentrifugation, which was defatted after dialysis.
SOURCE
Existing condition and distribution of lipoprotein
In blood, apo C-III binds to lipids, and is a structural element of VLDL and HDL.
CHEMICAL SYNTHESIS
Sites of synthesis:The liver and the small intestine.
The rate of synthesis:5.2mg/kg/day
METABOLISM
Metabolism
Apo C- III synthesized in the liver and small intestine, and present in VLDL, then transferred from VLDL to HDL.
Half life:1.0 days(Ref. 4506/4507)
GENETIC INFORMATION
Genetic information
Gene locus:11,
Gene arrangement (DNA)(Ref. 4115)
Information of genetic diseases:Information on genetic diseases (Apo C-IIIdeficiency).
Phenotypes:Further investigations are required.(Ref. 4508)
NOTE
Standard range:5.5- 9.5 mg/dl (in human sera)
Diseases and drugs that induce abnormal levels of apo C-III.
Apo C III deficiency
Analytical methods:TIA,ELISA,Nephelometry,SRID etc.
REFERENCES
[4115]
AUTHOR:Sharpe, C. R., Sidoli, A., Shelley, C. S., Lucero, M. A., Shoulders, C. C., and Baralle, F. E.
TITLE:Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance PubMed ID:6328445
JOURNAL:Nucleic Acids Res.
VOL:12 PAGE : 3917-3932 (1984)
[TOP]

[4408]
AUTHOR:Jackson,R.L., and Holdsworth,G.(1986) Isolation and Characterization of Apolipoproteins C-I, C-II, C-III, in Methods in ENZYMOLOGY Vol.128 (Segrest J.P., and Albers J.J., eds), pp223-246, Academic Press, Inc.
TITLE:
JOURNAL:
VOL: PAGE : - ()
[TOP]

[4501]
AUTHOR:Brewer, H.B. Jr., Shulman, R., Herbert,P., Ronan, R., and Wehrly ,K.
TITLE:The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins. PubMed ID:4846755
JOURNAL:J.Biol.Chem.
VOL:249 PAGE : 4975 -4984 (1974)
[TOP]

[4502]
AUTHOR:Segrest, J. P., Jackson, R. L., Morrisett, J. D., and Gotto, A. M., Jr.
TITLE:A molecular theory of lipid-protein interactions in the plasma lipoproteins PubMed ID:4368333
JOURNAL:FEBS Lett.
VOL:38 PAGE : 247-258 (1974)
[TOP]

[4503]
AUTHOR:Kashyap, M. L., Srivastava, L. S., Hynd, B. A., Gartside, P. S., and Perisutti, G.
TITLE:Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia PubMed ID:7288286
JOURNAL:J Lipid Res.
VOL:22 PAGE : 800-810 (1981)
[TOP]

[4504]
AUTHOR:Havel, R. J., Shore, V. G., Shore, B., and Bier, D. M.
TITLE:Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase PubMed ID:5507034
JOURNAL:Circ Res.
VOL:27 PAGE : 595-600 (1970)
[TOP]

[4505]
AUTHOR:Brown, W. V., and Baginsky, M. L.
TITLE:Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein PubMed ID:5057882
JOURNAL:Biochem Biophys Res Commun.
VOL:46 PAGE : 375-382 (1972)
[TOP]

[4506]
AUTHOR:Karathanasis, S. K., McPherson, J., Zannis, V. I., and Breslow, J. L.
TITLE:Linkage of human apolipoproteins A-I and C-III genes PubMed ID:6308458
JOURNAL:Nature.
VOL:304 PAGE : 371-373 (1983)
[TOP]

[4507]
AUTHOR:Schaefer,E.J., Jenkins, L.L., and Brewer,H.B. Jr.
TITLE:Human chylomicron apolipoprotein metabolism. PubMed ID:414755
JOURNAL:Biochem.Biophys.Res.Commun.
VOL:80 PAGE : 405 -412 (1978)
[TOP]

[4508]
AUTHOR:Norum, R. A., Lakier, J. B., Goldstein, S., Angel, A., Goldberg, R. B., Block, W. D., Noffze, D. K., Dolphin, P. J., Edelglass, J., Bogorad, D. D., et al.
TITLE:Familial deficiency of apolipoproteins A-I and C-III and precocious coronary-artery disease PubMed ID:7078608
JOURNAL:N Engl J Med.
VOL:306 PAGE : 1513-1519 (1982)
[TOP]

Last updated June 19, 2007. Copyright © 1989-2007 Japanese Conference on the Biochemistry of Lipids (JCBL). All rights reserved.